Bio-Technopark

In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On an area of 55,000 m2, the park now hosts 45 companies and many academic institutions representing a healthy mix of young start-ups and global companies as well as university clinics, institutes, and research groups.

read more

Leasing

In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with communal infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.

read more

Services

The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.

 

read more

News

Proteomedix appoints Dr Maurizio Ballerini, MD as VP Market Development EMEA and Dr Helene Peyro Saint-Paul, MD as Medical Advisor

Zurich-Schlieren, May 26, 2020. Proteomedix, the Swiss cancer diagnostics company is pleased to announce the appointment of Dr Maurizio Ballerini, MD as VP Market Development EMEA and Dr Helene Peyro Saint-Paul, MD, as Medical Advisor effective June 1, 2020. These accomplished executives bring a wealth of industry expertise to the...

read more

Analytical performance of Proclarix® verified

Zurich-Schlieren, Switzerland, May 19, 2020. Proteomedix, the Swiss cancer diagnostics company announces today the publication of the analytical performance results of Proclarix, Proteomedix lead product for improved prostate cancer diagnostics in the peer-reviewed journal PLOS ONE. The report published today highlights the analytical performance of the two CE-IVD assays that measure...

read more

Events